The glomerulus is a unique structure required for filtration of blood, while retaining plasma proteins based on size and charge selectivity. Distinct cell types form the structural unit that creates the filtration barrier. Structurally, fenestrated endothelial cells line the capillary loops and lie in close contact with mesangial cells. Podocytes are connected by specialized intercellular junctions known as slit diaphragms and separated from the endothelial compartment by the glomerular basement membrane. In order for this highly specialized structure to function, cross-communication between these cells must occur.
INTRODUCTION
Failure to adequately maintain glomerular barrier function results in loss of the size/charge selectivity of filtration, resulting in excretion of critical blood components into the urine. Loss of barrier function is characterized by proteinuria and observed in a large number of diseases. A number of cellular and structural defects lead to alterations in the glomerular filter, some of these result from impairment of the molecular signaling processes within and between the cells forming the glomerulus.
The development of the mature glomerulus consists of a series of tightly coordinated and well defined stages (reviewed in detail by [1] ). The cells that form the mature glomerulus include the podocytes that wrap around the glomerular capillaries, interdigitate, and connect by slit diaphragms that bridge the filtration slits (Fig. 1) . The intraglomerular mesangial cells remain situated in close contact with the glomerular endothelial cells that populate the side of the glomerular basement membrane opposite to the podocytes. The specialized endothelial cells lining the glomerular capillary loops are flattened and fenestrated, allowing the high flux required by filtration [1] (Fig. 1) . Advances in the development of targeted genomic deletion strategies in select cell types of the glomerulus, most notably the podocytes, have greatly increased our understanding of the communication within the glomerulus and identified the importance of specific signaling molecules that allow the formation and maintenance of the glomerular filtration barrier, in health and disease. This review aims to highlight recent discoveries of signaling systems that mediate intraglomerular crosstalk [2] .
Vascular endothelial growth factor a signaling
Vascular endothelial growth factor a (Vegfa) is of key importance for angiogenesis in multiple organ systems and remains important for the formation and maintenance of select microvascular beds within the kidney [3] [4] [5] . Vegfa expression by the podocytes has been shown to be a critical regulator of glomerular development and function, and precise regulation of the amount of Vegfa produced by podocytes is required for adequate barrier function [3, 6, 7] . The complex dosage sensitivity of Vegfa on glomerular health is further demonstrated in mouse models of diabetic nephropathy. In patients with diabetic renal sequelae, glomerular VEGFA increases. In mice, inducible deletion of Vegfa from podocytes results in endothelial injury and an accelerated progression of the glomerular damage in diabetes [8] . Conversely, overexpression of Vegfa in podocytes in diabetic mice worsens diabetic glomerulopathy [9] . Thus, achieving optimal levels of Vegfa in the podocytes in diabetic nephropathy may be a prerequisite for minimizing the progression of renal disease.
Given the important function and dosage sensitivity of Vegfa in the glomerulus, it is perhaps not surprising that mutations in genes that affect glomerular health also promote changes in glomerular Vegfa expression. However, in these settings, it remains to be determined whether the changes in Vegfa abundance occur as a cause or a consequence of glomerular disease. Recent findings have described that deletion of transforming growth factor (TGF)-b activated kinase 1 (TAK1) from podocytes results in early-onset proteinuria due to delayed glomerulogenesis and abnormal capillary formation. Importantly, these mice show an increased expression of Vegfa in podocytes [10 & ]. Expression profiling of glomeruli from mice following podocyte-specific deletion of the transcription factor, Tcf21/Pod1, showed a reduction in angiogenic factors including that of Vegfa and associated receptors, suggesting that this might be a regulatory factor for maintaining podocyte-endothelial vascular pathways [11] .
VEGFA produced in podocytes signals to the endothelium via VEGF receptors (VEGFR). Here, the VEGFR2 (Kdr/FLK-1) expressed by endothelial
KEY POINTS
Glomerular cross-communication is essential for the adequate development and maintenance of the glomerular filtration barrier.
Pathological alterations in intraglomerular signaling may facilitate or aggravate glomerulopathy.
Understanding these intraglomerular signaling pathways may allow the identification of novel pharmacological targets to help alleviate glomerular disease progression. cells appears most important as global deletion of Vegfr2 results in vascular defects, with glomerular thrombotic microangiopathy [12] . Signaling by VEGFA to the endothelial compartment via VEGFR1 vascular endothelial growth factor receptor 1; (FLT1) as well as neuropilin-1, that can act as a coreceptor, appears less important, as kinase-deficient VEGFR1 mice do not develop glomerular disease [13] . Intriguingly, podocytes produce the soluble form of Vegfr1, named soluble Flt1 (sFlt1) [13] . Deletion of Vegfr1 from podocytes leads to massive proteinuria, ultimately progressing to renal failure. Unexpectedly, the apparent phenotype resulted from effacement of podocyte foot processes, suggesting a primary defect in podocyte function. Importantly, the phenotype of the mice lacking Vegfr1 in podocytes could be rescued by breeding to a mouse carrying a truncated Vegfr1 allele lacking the kinase domain. As sFlt1 is transcribed from the Vegfr1 gene by alternative splicing, these observations demonstrate an important role for the soluble form of the receptor in glomerular health. It was found that sFlt1 secreted by the podocytes acts via an autocrine pathway, binding to glycosphingolipids in lipid rafts, initiating an intracellular signaling cascade, that facilitates actin reorganization and cell adhesion [13] . In experimental diabetes, inducible overexpression of sFlt1 in podocytes of mice has also been found to reduce albuminuria and ameliorate diabetic glomerulopathy [14] . Collectively, the Vegfa/Vegfr system plays a number of critical roles in intraglomerular communication, ultimately determining glomerular barrier function in health and disease (Fig. 2) .
The recent observations have confirmed and expanded important roles for the Vegfa signaling system within the glomerulus, both for crosscommunication with endothelial cells and via autocrine pathways. Few recent examples have demonstrated reverse signaling from the endothelial compartment to the podocytes. Vasohibin-1 has recently been described as an endothelial gene 
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Pdgf Ctgf Hgf Tgfb FIGURE 2. Summary of signaling pathways between the different cellular components of the glomerulus. Angpt1, angiopoietin-1; Ccr7, C-C chemokine receptor type 7; Cxcl12, C-X-C chemokine ligand 12; Cxcr, chemokine receptor; eNOS, endothelial nitric oxide synthase; ETA, endothelin-1 receptor A; Pdgfb, platelet-derived growth factor B; sFlt, soluble Flt; Tgfb, transforming growth factor-ß; TEK/Tie2, tyrosine-protein kinase receptor; Vegfa, vascular endothelial growth factor a.
that increases its expression in response to Vegfa. Vasohibin-1 affects endothelial cells in an autocrine manner, but may also have effects on podocytes and mesangial cells. Heterozygous deletion of vasohibin-1 in mice has been shown to exacerbate the effects of experimental diabetes by augmenting albuminuria and promoting podocyte injury [15] , suggesting that the protein may counteract Vegfa signaling, thereby ameliorating the effects of diabetic glomerulopathy.
Tie2/angiopoietin signaling
Similar to the Vegf-Vegfr paracrine system, angiopoietin-1 (Angpt1) is expressed by podocytes and mesangial cells and its cognate tyrosine kinase receptor, tyrosine-protein kinase receptor (Tie2/ Tek), is expressed by the glomerular endothelial cells. Both the Angpt1 and Angpt2 bind the Tie2 receptor and have classically been viewed as having opposing effects on microvascular development, with Angpt1 stabilizing the vasculature and Angpt2 antagonizing these effects by binding the Tie2 receptor in a competitive manner. Recent data have, however, suggested that Angpt1 and Angpt2 may cooperate to regulate Tie2 in lymphatic endothelium of the eye [16] . Global deletion of Angpt1 results in early embryonic lethality [17] , as does induced global deletion of Angpt1 before embryonic day (E) 12.5 [18] . In mice with induced deletion of Angpt1 at E10.5, defects were observed in the glomerulus, with dilated capillary loops and a disrupted structure of the subendothelial glomerular basement membrane [18] . Reductions in mesangial cells were noted, whereas podocytes seemed intact. Later induction of global Angpt1 deletion produced no overt phenotype in Angpt1-deficient mice. However, when these mice developed diabetes, the loss of Angpt1 led to profound changes in glomerular barrier function. As compared with diabetic wild-type mice, increased proteinuria was present in diabetic Angpt1-deficient mice, accompanied by mesangial matrix expansion and glomerulosclerosis. Importantly, using various Cre recombinase driver lines, it was found that only deletion of Angpt1 in both the podocytic and mesangial compartment could recapitulate the effects seen in global Angpt1-deficient mice after a diabetic challenge [18] . A reduction in intraglomerular Angpt1 expression has been noted in diabetes, suggesting that altered growth factor expression could influence glomerular changes accompanying the disease [19 ] . Repletion of the glomerular Angpt1, using selective podocytespecific overexpression of Angpt1 in diabetic mice, retarded the development of albuminuria as well as glomerular endothelial cell proliferation [19 & ]. Thus, Angpt1 plays an important role in glomerular health, and signaling of the Tie2/angiopoietin pathway appears to be indispensable for the maintenance of the filtration barrier during renal development and in pathophysiological conditions [18,19 & ]. Conversely, overexpression of Angpt2 in podocytes promotes apoptosis of glomerular endothelial cells and albuminuria, suggesting that within the glomerulus, Angpt2 may act in a competitive manner with Angpt1 [20] (Fig. 2) .
Recent studies have also shown important roles for angiopoietin-like-4 (Angptl4). The family of angiopoietin-like proteins share structural similarity with the angiopoietins, but do not signal via Tie2 receptors. Angptl4 is secreted as a glycoprotein from the cell. Podocyte expression of Angptl4 was substantially increased in rat models of puromycininduced nephrosis [21] . Targeted overexpression of Angptl4 in podocytes of rats leads to marked albuminuria, foot process effacement, and loss of ionic charges within the glomerular basement membrane. Importantly, when Angptl4 was expressed transgenically in rat adipose tissue, circulating levels of Angptl4 were markedly increased, but no change in albuminuria was noted. It was subsequently discovered that the Angptl4 secreted by podocytes in these forms of disease lacked normal sialylation (modification of the amount of sialic acids carried by glycoproteins). Increasing sialylation of Angptl4 decreased proteinuria in transgenic rats overexpressing Angptl4 in podocytes [21] . Thus, the expression and secretion of hyposialylated Angptl4 by podocytes is detrimental for glomerular ultrafiltration in puromycin-induced nephrosis. In a subsequent study, the authors discovered that proteinuriainduced increases in circulating normosialylated Angptl4 was protective in nephrotic models by binding to avb5 integrins on the glomerular endothelium, presumably protecting the endothelial cells from oxidative injury [22 & ]. However, as a consequence of high circulating levels of Angptl4 in nephrotic syndrome, free fatty acid uptake was also reduced in target organs and produced hypertriglyceridemia. Accordingly, normosialylated Angptl4 appears to contribute to glomerular health by communication with the endothelium, whereas the hyposialylated form accelerates oxidative injury in these disease states [22 & ] (Fig. 2 ).
C-X-C chemokine ligand 12/C-X-C chemokine receptor type 4/C-X-C chemokine receptor type 4 signaling
The stromal cell-derived factor 1/C-X-C chemokine ligand 12 (CXCL12) is a chemokine identified as playing an important role in glomerular cross-communication. Cxcl12 secretion has been noted in podocytes, acting on glomerular endothelial cells expressing the C-X-C chemokine receptor type 4 (CXCR4) [23] . Consistent with a role in cross-communication, mice lacking either Cxcl12 or Cxcr4 had similar renal phenotypes with altered blood vessel formation. Both transgenic strains were found to have ballooning of glomerular capillaries and altered pattering of the renal vasculature [23] . The role of Cxcl12 was evaluated using a selective Cxcl12 inhibitor in a mouse model of type 2 diabetes [24] . Inhibition of Cxcl12 significantly retarded the development of diabetic glomerulopathy. In particular, blockade of Cxcl12 signaling reduced diffuse glomerulosclerosis and prevented albuminuria in the diabetic model [24] . Subsequent studies have identified an additional factor in the signaling cascade, namely, CXCR7. Deletion of Cxcr7 in mice recapitulates the phenotype of the Cxcr4-deficient mice, with ballooning of glomerular capillaries. In contrast to Cxcr4, the Cxcr7 receptor is expressed by podocytes. Cxcr7 gene deletion also reduced the expression of Cxcr4, potentially explaining the observed phenotype. The authors speculate that Cxcr7 may function as a scavenger, thereby influencing Cxcl12 communication with Cxcr4 on endothelial cells [25] . The Cxcl12 signaling pathway may also play a role in potentiating Shiga toxin-induced renal injury. In fact, Shiga toxin increased the secretion of Cxcl12 and induced albuminuria, likely by altering endothelial permeability, whereas inhibition of the Cxcl12/Cxcr4 interaction led to improved survival and lower creatinine levels [26] ( Fig. 2 ).
Interleukin-6 signaling
Interleukin-6 secreted by podocytes has been shown important for the recruitment of leukocytes in vitro [27] . Here it was discovered that the presence of podocytes, which release interleukin-6, reduced tumor necrosis factor (TNF)-a-induced neutrophil recruitment to the glomerular endothelial cells. This immunosuppressive effect of interleukin-6 appeared to alter the presentation of chemokines on the glomerular endothelial cells [27] . Whether this cross-communication also occurs in the intact animal remains to be determined.
Activated protein C/protease-activated receptor signaling
Protein C is activated by components of the thrombomodulin-thrombin system, which reside on endothelial cells, including glomerular capillaries. Activated protein C (aPC) has been shown to play an important role in the setting of diabetic glomerulopathy. Mice carrying a point mutation in thrombomodulin, which has a severely reduced ability to generate aPC, shows an exaggerated glomerular response to diabetic induction, with increased apoptosis of endothelial cells and podocytes [28] . However, when these mice were backcrossed with mice carrying a gain of function activating mutation that allow conversion of protein C in the absence of thrombomodulin, the accelerated phenotype was attenuated [28] , strongly implicating a role for aPC signaling in the maintenance of glomerular barrier function in diabetes. The protective effects of aPC seem to depend on several receptor systems, in which the protease-activated receptors convey the signal in podocytes. Genetic ablation of the protease-activated receptor-3 in the lipopolysaccharide-induced podocyte injury model reduced the protective effects of aPC on podocytes [29] (Fig. 2) . These protective effects of aPC on podocytes may result from epigenetic changes that reduce oxidative stress [30] .
Transforming growth factor-b receptor 1/endothelin-1 signaling
The endothelin-1 system has recently been implicated in podocyte to endothelial crosscommunication.
Here it was found that inducible overexpression of the transforming growth factor-b receptor 1 (Tgfbr1) gene in podocytes, produced a phenotype with albuminuria and glomerulosclerosis in mice [31 && ]. Altered glomerular endothelial cell architecture appeared before evidence of foot process effacement and depletion of podocytes. Importantly, mitochondrial dysfunction and oxidative stress were noted in endothelial cells from transgenic mice overexpressing podocyte Tgfbr1. Expression profiling revealed that Tgfbr1 overexpression in podocytes increased endothelin-1 precursor abundance in podocytes and endothelin-1 receptor A (ETA) in adjacent endothelial cells [31 && ]. Additional proof that this signaling pathway is biologically important was obtained using an ETA antagonist in the setting of increased Tgfbr1 signaling in podocytes. Here the antagonist not only prevented mitochondrial dysfunction in the endothelium but also ameliorated the podocyte defects. Thus, endothelial ETA activation and resulting mitochondrial dysfunction appeared to be a prerequisite for podocyte apoptosis after stimulation of the Tgfbr1 pathway in podocytes [31 && ] (Fig. 2) . Aside from the effect of endothelin-1 on the endothelium, endothelin-1 receptors on the podocyte appear important for maintaining glomerular integrity in diabetes. As such, deletion of ETA and ETB receptors in the podocyte protected the mice from diabetic glomerulopathy [32] .
Endothelial-generated nitric oxide signaling
In the setting of experimental diabetes, genetic deletion of endothelial nitric oxide synthase (eNos) leads to increased albuminuria that cannot be attenuated by Vegfa receptor blockade [33] . This must be viewed in comparison to wild-type mice, where blockade of the Vegfa receptor decreased diabetic glomerulopathy, which is surprising as Vegfa has classically been described to signal via eNos. Interestingly, inducible overexpression of podocytic Vegfa in eNos-deficient mice results in marked proteinuria and glomerulosclerosis, further confirming nitric oxide independent effects of Vegfa [34] . Thus, loss of eNos may aggravate the diabetic condition independent of Vegfa. In fact, lack of eNos results in early-onset albuminuria and changes in podocyte architecture in diabetic mice, not observed in wildtype diabetic mice (Fig. 2 ). Furthermore, these sequelae can be blocked by inhibiting the reninangiotensin-aldosterone system [33] . As eNos is situated on endothelial cells, some form of crosscommunication must occur with the podocytes and eNos deficiency may thus trigger harmful responses in a renin-angiotensin-aldosterone system-dependent manner.
CROSS-COMMUNICATION BETWEEN INTRAGLOMERULAR ENDOTHELIAL AND MESANGIAL CELLS
Classical studies have delineated a key role for the platelet-derived growth factor B (Pdgfb) in communication between the glomerular endothelium and nearby mesangial cells. As such, endothelial cells express Pdgfb, whereas its receptor (Pdgfrb) resides on pericytes, including the specialized mesangial cells [35] . Genetic ablation of Pdgfb in mice disrupts the formation of capillaries, due to failure to attract pericyte progenitors, resulting in early embryonic lethality [36] . In these animals, absence of mesangial cells leads to the formation of a single ballooned glomerular capillary loop [35] . Targeted deletion of Pdgfrb generates a similar glomerular phenotype, indicating true endothelialmesangial communication [37] . Selective deletion of endothelial-derived Pdgfb produces a milder phenotype, where most animals reached adulthood. However, they did still develop glomerular abnormalities [38] (Fig. 2) .
Signal transduction in the mesangial-endothelial direction must also occur. The close proximity of the mesangial and endothelial cells likely allows for efficient signaling, without the presence of massive amounts of ligand. At present, few mesangial-secreted factors have been identified that partake in glomerular endothelial cross-communication in vivo. As noted previously, deletion of Angpt1 from both podocytes and mesangial cells was necessary to obtain similar dramatic alterations in barrier function after experimental diabetes as observed in mice with a global deletion of Angpt1 [18] . Another example of mesangial to endothelial communication involves integrin avb8. The integrin is expressed by mesangial cells, where it sequesters TGF-b, thereby reducing TGF-b signaling. Deletion of integrin avb8 results in early mortality, albuminuria, and glomerulopathy in mice. These effects were ascribed to increased local bioavailability of TGF-b, which promoted apoptosis by acting on glomerular endothelial cells [39] . Regulation of integrin avb8 by the mesangial cells may therefore amend TGF-b signaling to the endothelial cells ( Fig. 2 ).
CROSS-COMMUNICATION BETWEEN PODOCYTES AND MESANGIAL CELLS
Until now, the, direct in-vivo evidence for communication between podocytes and mesangial cells has been scarce. However, some signaling is likely to occur as specific injury of the podocytes clearly affects mesangial cell morphology and function. However, it cannot be excluded that disrupted mesangial function develops because of altered endothelial signaling after podocyte injury, as endothelial Pdgfb remains essential for mesangial cell function. Several signaling pathways have been suggested to be involved in this type of signaling, including endothelin-1, C-C chemokine receptor type 7 (CCR7) and its ligand chemokine (C-C motif) ligand 21 (SLC/CCL21), platelet-derived growth factor, connective tissue growth factor, hepatocyte growth factor, and TGF-b [40] (Fig. 2) .
CONCLUSION
The increased application of cell-specific transgenic models and better methods to identify signaling pathways and regulators have greatly advanced our understanding of glomerular cross-communication in vivo. However, novel ligands allowing paracrine signaling, especially those released from intraglomerular mesangial and endothelial cells, likely remain to be discovered. The identification of these mediators, as well as a better understanding of already established signaling pathways, should provide new targets for the prevention and treatment of glomerular diseases.
